Lineage Cell Therapeutics (LCTX) Stock: Buy, Sell, or Hold?
LCTX - Lineage Cell Therapeutics, Inc.
$1.01
-0.02 (-1.94%)
▼
5d:
+0.0%
30d:
-8.18%
90d:
-16.53%
BUY
HIGH Confidence
Analysis Updated: Sep 17, 2026 12:00 AM ET
Earnings: Nov 05, 2026
Get Alerted When LCTX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: LCTX shows strong fundamentals and good volume confirmation. Solid entry point despite fair pricing.
✅ BUY SIGNAL: LCTX shows strong fundamentals and good volume confirmation. Solid entry point despite fair pricing.
In-depth Analysis How we analyze
Valuation Analysis: LCTX is currently trading at $1.01, which is considered fair relative to its 30-day fair value range of $1.05 to $1.12.
Technical Outlook: Technically, LCTX is in a strong uptrend. The price is currently testing key support at $1.00. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: LCTX scores 73/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $5.50 (+434.0%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, LCTX is in a strong uptrend. The price is currently testing key support at $1.00. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: LCTX scores 73/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $5.50 (+434.0%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$1.05 -
$1.12
Company Quality Score
63/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
86.8%
All Signals
- NEUTRAL: Price in fair range
- BULLISH: Strong technical setup (73/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 434.0% below Wall St target ($5.50)
- BULLISH: Bottoming setup score 73/100 — corrected, stabilizing, and turning up
Trading Range Analysis
30-Day Trading Range
$1.05 -
$1.12
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$1.00
Resistance Level
$1.16
Current Trend
Strong Uptrend
Technical data as of
Sep 17, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-10.10
Wall Street Target
$5.50
(+434.0%)
Revenue Growth (YoY)
-61.3%
Profit Margin
-246.6%
Share & Embed Analysis
Last updated: September 18, 2026 11:13 AM ET
Data refreshes hourly during market hours. Next update: 12:13 PM
Data refreshes hourly during market hours. Next update: 12:13 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is LCTX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$91 | 57 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$285 | 46 HOLD |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$34 | 60 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$36 | 44 HOLD |
|
VRDN
Viridian Therapeutics Inc |
STRONG BUY
16 analysts |
$37 | 67 BUY |
